A phase 2 randomized, double-blind study of AMG 108, a fully human monoclonal antibody to IL-1R, in patients with rheumatoid arthritis

Arthritis Research and Therapy

Volumn 12, Issue 5, 2010, Pages

  Cardiel, Mario H ^a   Tak, Paul P ^b   Bensen, William ^c   Burch, Francis X ^d   Forejtova, Sarka ^e   Badurski, Janusz E ^f   Kakkar, Tarundeep ^g   Bevirt, Terry ^g   Ni, Liyun ^g   McCroskery, Ellen ^g   Jahreis, Angelika ^g   Zack, Debra J ^g  

^a Centro de Investigacion Clinica de Morelia   (Mexico)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c ST JOSEPH S HOSPITAL   (Canada)

^d San Antonio Center for Clinical Research   (United States)

^e INSTITUTE OF RHEUMATOLOGY   (Czech Republic)

^f Centrum Osteoporozy I Chorób Kostno Stawowych   (Poland)

^g AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 108; C REACTIVE PROTEIN; METHOTREXATE; MONOCLONAL ANTIBODY; PLACEBO; PREDNISONE; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; INTERLEUKIN 1 RECEPTOR;

ACUTE PHASE RESPONSE; ADULT; AGED; ARTICLE; DIARRHEA; DISEASE ACTIVITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEADACHE; HUMAN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; PAIN ASSESSMENT; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SCORING SYSTEM; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VISUAL ANALOG SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; IMMUNOLOGY; MIDDLE AGED;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PAIN MEASUREMENT; RECEPTORS, INTERLEUKIN-1;

EID: 77957893502     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3163     Document Type: Article

References (31)

1. Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, Spitz PW, Haga M, Kleinheksel SM, Cathey MA. The mortality of rheumatoid arthritis. Arthritis Rheum 1994, 37:481-494. 10.1002/art.1780370408, 8147925.
2. Plenge RM, Padyukov L, Remmers EF, Purcell S, Lee AT, Karlson EW, Wolfe F, Kastner DL, Alfredsson L, Altshuler D, Gregersen PK, Klareskog L, Rioux JD. Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. Am J Hum Genet 2005, 77:1044-1060. 10.1086/498651, 1285162, 16380915.
3. Tak PP, Smeets TJ, Daha MR, Kluin PM, Meijers KA, Brand R, Meinders AE, Breedveld FC. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum 1997, 40:217-225. 10.1002/art.1780400206, 9041933.
4. Tak PP, Bresnihan B. The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis. Arthritis Rheum 2000, 43:2619-2633. 10.1002/1529-0131(200012)43:12<2619::AID-ANR1>3.0.CO;2-V, 11145019.
5. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003, 423:356-361. 10.1038/nature01661, 12748655.
6. Lee SK, Gardner AE, Kalinowski JF, Jastrzebski SL, Lorenzo JA. RANKL-stimulated osteoclast-like cell formation in vitro is partially dependent on endogenous interleukin-1 production. Bone 2006, 38:678-685. 10.1016/j.bone.2005.10.011, 16309985.
7. Kim JH, Jin HM, Kim K, Song I, Youn BU, Matsuo K, Kim N. The mechanism of osteoclast differentiation induced by IL-1. J Immunol 2009, 183:1862-1870. 10.4049/jimmunol.0803007, 19587010.
8. Joosten LA, Helsen MM, van de Loo FA, van den Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum 1996, 39:797-809. 10.1002/art.1780390513, 8639177.
9. van de Loo FA, Joosten LA, van Lent PL, Arntz OJ, van den Berg WB. Role of interleukin-1, tumor necrosis factor alpha, and interleukin-6 in cartilage proteoglycan metabolism and destruction. Effect of in situ blocking in murine antigen- and zymosan-induced arthritis. Arthritis Rheum 1995, 38:164-172. 10.1002/art.1780380204, 7848306.
10. van Meurs JB, van Lent PL, Bayne EK, van de Loo FA, van den Berg WB. Interleukin-1 receptor antagonist prevents expression of the metalloproteinase-generated neoepitope VDIPEN in antigen-induced arthritis. Arthritis Rheum 1998, 41:647-656. 10.1002/1529-0131(199804)41:4<647::AID-ART11>3.0.CO;2-T, 9550473.
11. Monach PA, Benoist C, Mathis D. The role of antibodies in mouse models of rheumatoid arthritis, and relevance to human disease. Adv Immunol 2004, 82:217-248. full_text, 14975258.
12. Horai R, Saijo S, Tanioka H, Nakae S, Sudo K, Okahara A, Ikuse T, Asano M, Iwakura Y. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 2000, 191:313-320. 10.1084/jem.191.2.313, 2195765, 10637275.
13. Burger D, Dayer JM, Palmer G, Gabay C. Is IL-1 a good therapeutic target in the treatment of arthritis?. Best Pract Res Clin Rheumatol 2006, 20:879-896. 10.1016/j.berh.2006.06.004, 16980212.
14. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324. 10.1002/art.1780310302, 3358796.
15. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992, 35:498-502. 10.1002/art.1780350502, 1575785.
16. ICH Good Clinical Practices. , http://www.ich.org/LOB/media/MEDIA482.pdf
17. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Katz LM, Lightfoot R, Paulus H, Strand V, Tugwell P, Weinblatt M, Williams HJ, Wolfe F, Kieszak S. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995, 38:727-735. 10.1002/art.1780380602, 7779114.
18. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:44-48. 10.1002/art.1780380107, 7818570.
19. Bruce B, Fries JF. The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol 2005, 23:S14-S18.
20. Brazier JE, Harper R, Jones NM, O'Cathain A, Thomas KJ, Usherwood T, Westlake L. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 1992, 305:160-164. 10.1136/bmj.305.6846.160, 1883187, 1285753.
21. Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993, 20:557-560.
22. Ren K, Torres R. Role of interleukin-1β during pain and inflammation. Brain Res Rev 2009, 60:57-64. 10.1016/j.brainresrev.2008.12.020, 19166877.
23. Eklund CM. Proinflammatory cytokines in CRP baseline regulation. Adv Clin Chem 2009, 48:111-136. full_text, 19803417.
24. Molto A, Olive A. Anti-IL-1 molecules: new comers and new indications. Joint Bone Spine 2010, 77:102-107. 10.1016/j.jbspin.2009.10.011, 20045371.
25. Rudolphi K, Gerwin N, Verzijl N, van der Kraan P, van den Berg W. Pralnacasan, an inhibitor of interleukin-1β converting enzyme, reduces joint damage in two murine models of osteoarthritis. Osteoarthritis Cartilage 2003, 11:738-746. 10.1016/S1063-4584(03)00153-5, 13129693.
26. Gabay C. IL-1 trap. Regeneron/Novartis. Curr Opin Investig Drugs 2003, 4:593-597.
27. Mertens M, Singh JA. Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol 2009, 36:1118-1125. 10.3899/jrheum.090074, 19447938.
28. Kalliolias GD, Liossis SN. The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis. Expert Opin Investig Drugs 2008, 17:349-359. 10.1517/13543784.17.3.349, 18321234.
29. Stahl N, Radin A, Mellis S. Rilonacept - CAPS and beyond. Ann N Y Acad Sci 2009, 1182:124-134. 10.1111/j.1749-6632.2009.05074.x, 20074281.
30. Bevaart L, Vervoordeldonk MJ, Tak PP. Evaluation of therapeutic targets in animal models of arthritis: how does it relate to rheumatoid arthritis?. Arthritis Rheum 2010, 62:2192-2205. 10.1002/art.27503, 20506322.
31. Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol 2005, 23:S93-S99.